MS4A1 and acute lymphoblastic leukemia: On the other hand, the comparison of the treatment composed of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone with ofatumumab (HCVAD-O) to the historical cohort of B-ALL CD20+ Ph- patients treated with HCVAD with rituximab (HCVAD-R) showed improvement in event-free survival (EFS) and overall survival (OS) (56).